Novel therapies emerging in oncology to target the TGF-β pathway.

Background

The transforming growth factor-β (TGF-β) signaling pathway regulates a multitude of key processes including cellular growth, differentiation, apoptosis, motility, invasion, extracellular matrix production, angiogenesis, immune responses [ 1 , 2 ]. Recent advances in understanding the molecular details of the TGF-β signaling cascade, and crosstalk with other pathways, have led to a more coherent roadmap of the programs governed by TGF-β [ 3 – 5 ]. However, difficulty in defining the effect of TGF-β stems from the context-dependent nature of the cytokines effect on different cell types. Cell fate decisions are not determined simply by the available nutrients in the surrounding environment but controlled by a network of communication signals.

TGF-β1, 2 and 3 are evolutionarily conserved, secreted, isoforms that are encoded as large protein precursors with 70–80% homology that govern fundamental aspects of cellular behavior [ 6 , 7 ]. TGF-β is synthesized in a latent form that must be activated to allow for engagement of a tetrameric receptor complex composed of TGF-β receptors I and II (TGF-βRI, TGF-βRII). Activated TGF-β complexes, with additional factors, form a serine/threonine kinase complex that binds to TGF-β receptors composed of both type I and type II receptor subunits. After the binding of TGF-β, the type 2 receptor kinase (TGF-βRII ) promotes heterotetramerization and phosphorylation that activates the type 1 receptor kinase (TGF-β RI), followed by phosphorylation of Smad2/Smad3 triggering a signaling cascade.

Activation of the TGF-β signaling pathway can elicit either tumor-suppressing or tumor-promoting effects in a cell- and context-dependent manner (Fig. 1 ). In normal tissues, these effects maintain homeostasis and prevent the early stages of tumor formation [ 8 ]. In healthy cells, TGF-β halts the cell cycle at G1 to reduce proliferation, induce differentiation and may promote apoptosis [ 4 , 9 , 10 ]. Activated Smad proteins associate with Smad4 and translocate to the nucleus where they recruit additional transcription factors, DNA-binding transcription factors, co-repressors, co-activators and chromatin remodeling factors. Differential expression of these factors may be responsible for the cell-type and context-dependent response to TGF-β. Nuclear localized SMAD2/3/4 complex induces tumor-promoting effects through cell proliferation ( PDGF -β ), immune suppression ( Foxp3 ), EMT activation ( SNAIL/SLUG, ZEB1/ZEB2, HMGA2) , EMT suppression (E-Cadherin, Cytokeratin) and metastasis ( HDM2, MMP-9) . Tumor-suppressing effects inhibit cell proliferation ( p15, p21, p57, 4E-BP1 ), apoptosis ( Bim, DAPK, GADD45 β), and autophagy ( ATG5, ATG7, Beclin-1 ), suppress inflammation ( Foxp3 ) and block angiogenesis ( Thrombospondin ). Fig. 1 Agents in Development to Target the TGF-β Pathway in Oncology. Shown are noteworthy antagonists that target the TGF-β pathway and have recently been evaluated in clinical trials or are in clinical development. As indicated, many steps within the TGF-β pathway have been targeted therapeutically. Key tumor-promoting and tumor-suppressing genes transcriptionally regulated by the TGF-β pathwat are indicated

In cancer cells, the TGF-β signaling pathway is deregulated or mutated, and TGF-β no longer controls proliferation. As a result of mutations or epigenetic modifications introduced during cancer progression, tumors can become resistant to the suppressive effects of TGF-β signaling [ 11 ]. TGF-β1 signaling is hyperactivated in breast cancer, which drives cancer progression and metastasis [ 12 ]. Novel regulators of SMAD7, including OTU domain-containing protein 1 (OTUD1) and ubiquitin-specific protease 26 (USP26), attenuate TGF-β1-mediated aggressive phenotypes in breast cancer. SMAD7 is an antagonist of the TGF-β1 signaling pathway forming stable complexes with TGF-βRI to inhibit R-SMAD phosphorylation and downstream signaling. In colon cancer, SMAD7 deletion predisposes to a favorable prognosis compared to patients with two copies of the gene, whereas patients with SMAD7 gene amplification exhibit significantly worse outcomes [ 13 ]. TGF-β1 and BMP-7 (bone morphogenetic protein-7), major members of the TGF-β family of receptor ligands, activate downstream signaling pathways and their respective target genes to counter-regulate biological outcomes. BMP7 deficiency accelerates tumorigenesis and negatively correlates with patient survival in prostate cancer [ 14 ]. Human prostatic carcinomas generally exhibit significantly lower levels of BMP7 transcripts compared to the normal-appearing gland; daily injections of recombinant BMP-7 protein reduced tumor burden and metastasis in mice transplanted with prostate cancer cell lines directly into the prostate or bone. Loss of BMP7 in glioblastoma, breast and prostate cancers, predisposes to enhanced EMT and acquisition of invasive/metastatic traits suggesting a protective role for BMP7 in cancer progression. Understanding the mechanisms by which the tumor-suppressing or tumor-promoting effects of TGF-β signaling can be regulated may have therapeutic potential for inhibiting the progression of several different types of human cancer.

In the tumor microenvironment (TME), TGF-β contributes to favorable tumor growth, invasion and metastatic spread. Advanced tumors produce excessive amounts of TGF-β which, in normal epithelial cells, is a potent growth inhibitor. However, in oncogenically activated cells, the homeostatic action of TGF-β is diverted along alternate pathways and elicits protective or tumor-suppressive effects during the early growth-sensitive stages of tumorigenesis. At late stages of malignancy, tumor progression is driven by TGF-β overload. The TME is a target of TGF-β action that stimulates tumor progression through pro-tumorigenic effects on tumor cells as well as vascular, immune and fibroblastic cells [ 4 , 9 , 10 ].

Epithelial to mesenchymal transition (EMT) is a multi-step, plastic and reversible process during which cells lose epithelial characteristics and gain properties of mesenchymal cells. The transition in cellular phenotype from EMT plays a critical role in tumorigenesis, tumor invasion and metastasis [ 15 , 16 ], unless the mesenchymal phenotype becomes fixed by subsequent epigenetic changes or additional genetic mutations. The plasticity and reversibility of EMT in response to changing local TGF-β levels have clearly demonstrated in vitro and in vivo. TGF-β-induced EMT is an attractive druggable target since it is thought to drive a more stem cell-like phenotype which is critical for tumor progression, dissemination, homing and colony-initiating activity. Inhibiting TGF-β may reduce the stem cell-like tumor compartment which displays chemotherapeutic resistance.

TGF-β effect on escape from immune surveillance

TGF-β modulates the level and functional activity of numerous immune cell types to exert systemic antitumor immune suppression and inhibit host immunosurveillance [ 17 – 19 ], (Fig. 2 ). In addition to direct effects on tumor cells, TGF-β regulates infiltration of inflammatory, immune cells and cancer-associated fibroblasts in the TME [ 20 – 25 ]. Neutralizing TGF-β enhances CD8 + T-cell- and NK-cell-mediated antitumor immune responses and increases neutrophil-attracting chemokines resulting in recruitment and activation of neutrophils with an antitumor phenotype. TGF-β also inhibits naïve T cell differentiation into the Th1 phenotype that is the most prominent and best-characterized T cell response against cancer. TGF-β further inhibits T cell proliferation and effector function by silencing expression of IL-2, the cytokine that elicits subsequent CD4 + T cell proliferation. TGF-β signaling directly inhibits the cytotoxic program of CD8 + T cells through mechanisms which stimulate SMADs and transcription factor ATF1 to repress granzyme B and IFN-γ, involved the lytic function of CD8 + T cells [ 25 ]. Fig. 2 Effects of TGF-β on Antitumor Immunity. TGF-β is produced by multiple cell types within the TME. TGF-β can increase (black arrow) or decrease (red block) the proliferation and functional activity of immune effectors with tumor-promoting or tumor-suppressive outcomes. TGF-β enhances pro-inflammatory Th17 cells along with IL-6. TGF-β also blocks the IFN-γ-mediated induction of pro-inflammatory Th1 cells as well as the IL-4-dependent production of Th2 cells to decrease tumor suppression. TGF-β induces naïve T cell differentiation into Tregs and Treg expansion with IL-2. Tregs then reduce CD8 + T cell development and expansion to increase immune suppression. TGF-β also reduces the production of mast cells (to reduce superoxide and NO production), natural killer (NK) cells (reduced cytokine and IFN-γ production), B cells (reduced IgA secretion), polymorphonuclear cells (PMNs, reduced degranulation), M1 macrophages (reduced pro-inflammatory cytokines, e.g., IL-12) and reduced dendritic cells (DCs) leading to reduced antigen presentation and cytokine production. TGF-β promotes the differentiation and expansion of MDSCs as well as the production of M2 macrophages leading to increased anti-inflammatory cytokines IL-4 and IL-10

Regulatory T cells (Tregs) suppress the activity of effector T cells to maintain immune homeostasis, and their number is increased in the TME. Tregs facilitate immune evasion and are stimulated to expand and differentiate by TGF-β. TGF-β in combination with IL-2 enforces a suppressor phenotype in ex vivo naïve CD4 + T cells by triggering expression of FOXP3, the master transcription factor of the Treg program [ 26 , 27 ]. Treg functionality is mediated by TGF-β secretion, and Foxp3 upregulation by TGF-β is mediated by both Smad2 and Smad3 [ 28 ]. An environment rich in pro-inflammatory cytokines counteracts TGF-β-driven induction of Tregs as it favors differentiation of CD4 + T cells toward an effector phenotype [ 29 – 32 ].

TGF-β signaling suppresses the generation and function of NK cells by silencing IFN-γ and Th1 transcription factor T-bet expression in NK cells, thus inhibiting Th1 responses [ 33 – 37 ]. Pro-inflammatory signals counteract this mechanism by decreasing TGF-β II levels and suppressing downstream SMAD signaling in NK cells. TGF-β signaling inhibits the expression of NKG2D and NKp30, two surface receptors of NK cells that mediate the recognition of stressed and malignant transformed cells [ 36 , 37 ]. Dendritic cells (DCs) are highly potent antigen-presenting cells and play a key role in tumor immunity and in the regulation of Th1 and Treg-mediated immune responses [ 38 – 42 ]. TGF-β inhibits the antigen presentation capability of DCs in vitro by suppressing MHCII gene expression. Cancer cells direct DCs to secrete TGF-β, which in turn induces conversion of naïve CD4 + T cells into Tregs.

The TME also polarizes macrophages toward a M2 phenotype with anti-inflammatory, immunosuppressive and pro-angiogenic functions [ 43 – 47 ]. Tumor-associated macrophages (TAMs) produce TGF-β and subsets of macrophages that can mobilize active TGF-β through the activity of integrin αv β8 and MMP1. TGF-β acts as chemoattractant for monocytes to the sites of inflammation and upregulates adhesion molecules that enable monocyte attachment to the ECM. Monocytes differentiate into perivascular macrophages and facilitate tumor cell extravasation by promoting blood vessel leakiness. A TGF-β-rich TME may contribute to immune evasion by dampening the inflammatory functions of macrophages.

TGF-β1-mediated programming of nascent myeloid-derived suppressor cells (MDSCs) leads to a potent antitumor phenotype potentially suitable for adoptive immunotherapy [ 48 , 49 ]. TGF-β is involved in controlling MDSC differentiation and immunoregulatory function in vivo, and MDSCs regulate T cell immunity. TGF-β increases expansion of the monocytic MDSC (Mo-MDSC) population, expression of immunosuppressive molecules by MDSCs and the ability of MDSCs to suppress CD4 + T cell proliferation [ 50 ].

TGF-β is a pleiotropic cytokine with a crucial function in mediating immune suppression and evasion of immunosurveillance in the TME. TGF-β produced by T cells has been shown to be an important factor for suppressing antitumor immune responses, but the precise role of tumor-derived TGF-β has been poorly understood. Knockdown of tumor-derived TGF-β using shRNA resulted in dramatically reduced tumor size, slowed tumor formation, prolonged survival of tumor-bearing mice and inhibited metastatic growth [ 51 ]. Mechanistically, reducing the number of MDSCs and CD4 + Foxp3 + Treg cells, enhanced IFN-γ production by CTLs. Knockdown of tumor-derived TGF-β also significantly reduced the conversion of naive CD4 + T cells into Treg cells in vitro. Knockdown of TGF-β also suppressed cell migration. TGF-β has also been found to be particularly important for the maintenance of low affinity CD4 + T cells [ 52 ]. In the absence of TGF-β, IL-7Rα expression positively correlated with TCR affinity, as TGF-βRII-deficient T cells bearing higher affinity TCRs expressed increased amounts of IL-7Rα and, thus, exhibited better homeostatic survival than their lower affinity counterparts.

Chimeric antigen receptor–modified T cell (CAR T cell) therapy has proven to be a promising approach against eliminating solid tumors, but the immunosuppressive TME remains a significant obstacle. Knocking out the endogenous TGF-β receptor II ( TGFBR2 ) in CAR T cells with CRISPR/Cas9 technology was an approach used to reduce the induced Treg conversion and prevent CAR T exhaustion. TGFBR2 -edited CAR T cells had better in vivo tumor elimination efficacy, both in cell line–derived xenograft and patient-derived xenograft solid tumor models, whether administered locally or systemically [ 53 ]. Knocking out endogenous TGFBR2 greatly improved the in vivo function of CAR T cells in TGF-β–rich TME. The potency of CAR T cells directed to prostate-specific membrane antigen (PSMA) was also enhanced by co-expression of a dominant-negative TGF-βRII (dnTGF-βRII) [ 54 ]. Expression of the dnTGF-βRII in CAR T cells increased lymphocyte proliferation, enhanced cytokine secretion, promoted T cell resistance to exhaustion and increased tumor eradication in aggressive human prostate cancer models.

TGF-β pathway biomarkers to predict cancer risk and therapeutic response

Blood, serum and tissue markers

Measurement of TGF-β pathway components in blood, serum and tissue represents a rapid, accurate and inexpensive approach to determine cancer risk, stratify patients into treatment populations and predict therapeutic response. Early detection of tumors generally improves patient survival, and patients diagnosed at an advanced stage have poorer prognosis. Increased TGF-β levels within the primary tumor as well as high plasma levels of TGF-β correlate with poor prognosis in CRC patients [ 55 , 56 ]. TGF-β expression is increased in pancreatic cancer and associated with poor prognosis [ 57 , 58 ]. TGF-β is also highly expressed in HCC, and TGF-β1 levels are associated with disease progression and poor outcome [ 59 ]. While during the early phases TGF-β inhibits proliferation of premalignant hepatocytes, later it promotes stromal formation, EMT and invasion [ 60 ]. Elevated serum TGF concentration at diagnosis in MM patients may be a favorable predictor of response [ 61 ].

A nested case-controlled study using a large real-world population-based dataset exhibited that low serum TGF-β1 concentrations predict death from HCC, with a 160% increase in the risk per one SD decrease in the TGF-β1 concentrations [ 62 ], This association remained statistically significant even after adjusting for confounding factors and in a sensitivity analysis restricted to participants who survived for at least five years after the baseline survey, effectively eliminating the possibility that these patients had undiagnosed HCC at the baseline survey. The data demonstrate that low levels of TGF-β1 can identify patients who are at higher risk of developing HCC. Furthermore, the predictive value was significantly higher among HCV-positive patients. TGF-β1 may be a serum predictor that becomes altered well before the development of clinically detectable malignancy. The findings are in agreement with the general theory that TGF-β1 is frequently present in the tumor microenvironment and prevents premalignant progression during the beginning phases of carcinogenesis.

Gene expression and transcriptomics

Signatures identified by gene expression and transcriptomic profiling may serve as diagnostic aids and improve predicting and treatment response compared to single biomarkers. The molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) consortium are performing three two-stage single-arm multi-center open-label phase II studies in molecular- and gene expression-selected mCRC populations. In one treatment cohort, patients with chemotherapy-resistant activated TGF-β signature-like tumors will have received 5FU or capecitabine in the first line of chemotherapy, usually combined with oxaliplatin. Newly identified biomarkers may be included to identify alternative combinations for patients susceptible of developing secondary resistance.

Immune markers

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success in the treatment of different cancer types, but only a subset of patients derive clinical benefit [ 63 ]. TGF-β signaling pathway participated in cancer immune escape and ICI resistance. Concurrent TGF-β blockade might be a feasible strategy to enhance the efficacy of immunotherapy and relieve immune checkpoint inhibitor resistance [ 64 ]. Selective inhibition of TGF-β1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape [ 65 ]. Biomarkers superior to tumor mutational burden would greatly enhance patient selection for immune checkpoint inhibitor therapies.

Agents in clinical development to target the TGF-β pathway in oncology

Despite significant advancements in the diagnosis and treatment of certain cancer types, overall survival (OS) in many cancers has remained relatively constant. Poor initial response rates and the emergence of drug resistance remain significant challenges. Cancer investigators strive to develop more-effective treatments that have fewer side effects than do standard cancer therapies. A number of receptor kinase inhibitors, monoclonal antibodies (mAbs), ligand traps, antisense oligonucleotides and vaccines have been designed to target the TGF-β pathway and have been evaluated clinically (Fig. 1 ). Many of these of agents have been or are being evaluated in clinical trials to treat a number of different cancer types (Tables 1 , 2 ). Table 1 Completed clinical trials that evaluated TGF-β pathway antagonists in oncology Study NCT Registry Number Agent Target(s) Study Population Number of Patients Phase Clinical Efficacy Most Frequent Adverse Events Small molecule receptor kinase inhibitors NCT02160106 Vactosertib TGF-β RI Solid tumors 29 I Pharmacokinetics (TEW-7197) 35 I Dosing model NCT01682187 Galunisertib (LY2157299) TGF-β RI Advanced solid tumors 65 I Glioma population ORR 14% Thrombocytopenia thrombosis, dyspnea NCT01582269 Galunisertib ± Lomustine TGF-β RI Refractory glioma 180 II mOS: Galunisertib 8 m, Lomustine 7 m, Both 6.5 m Fatigue, nausea, vomiting NCT01220271 Temozolomide RT ± Galunisertib CT/RT TGF-β RI GBM 75 Ib/II mOS 18.2 vs. 17.9 m Fatigue, nausea constipation NCT01373164 Galunisertib ± Gemcitabine TGF-β RI Chemotherapy Inoperable or metastatic pancreatic 170 I/II mOS 8.9 vs. 7.1 m Neutropenia, thrombocytopenia NCT02154646 Galunisertib + Gemcitabine TGF-β RI Chemotherapy Inoperable or metastatic pancreatic cancer 9 I ORR 0% Elevated liver enzymes NCT02734160 Galunisertib + Durvalumab TGF-β RI PD-L1 Metastatic pancreatic cancer 32 I ORR 3% mPFS 1.9 Elevated liver enzymes neutropenia NCT02240433 Galunisertib + Sorafenib TGF-β RI TKI, Angiogenesis Metastatic HCC 14 I ORR 9% Hypophosphatemia Hand-foot syndrome NCT01246986 Galunisertib TGF-β RI Metastatic HCC 147 II mPFS: 2.7 m (part A) 4.2 m (part B) Neutropenia Antibodies NCT00356460 Fresolimumab TGF-β1, β2, β3 Advanced melanoma Renal cell cancer 29 I ORR 3 and 5% mPFS 2.75 m Keratoacanthomas hyperkeratosis NCT01472731 Fresolimumab RT TGF-β1, β2, β3 Glioma 23 II ORR 0% Fatigue, anemia keratoacanthomas NCT01646203 LY3022859 TGF-β RII Advanced solid Tumors 14 I Not reported CRS Ligand Traps NCT04296942 Bintrafusp alfa, BN-Brachyury, Entinostat, Adotrastuzumab Emtansine TGF-β RII and PD-L1 Advanced Stage Breast cancer 19 I ORR 21% Bullous pemphigoid increased lipase, colitis NCT03427411 Bintrafusp alfa TGF-β RII and PD-L1 HPV-positive advanced solid tumors 120 (estimated enrollment) II ORR 39% Colitis, hypokalemia gastroparesis NCT02517398 Bintrafusp alfa TGF-β RII and PD-L1 Pre-treated cervical tumors 25 I ORR 28% Hypokalemia NCT02517398 Bintrafusp alfa TGF-β RII and PD-L1 Refractory head and neck cancer 32 I ORR 22% Keratoacanthomas hyperglycemia NCT02517398 Bintrafusp alfa TGF-β RII and PD-L1 Pre-treated NSCLC 80 II PD-L1 > 1%, ORR 40% PD-L1 > 80%,ORR 71% Keratoacanthomas NCT02517398 Bintrafusp alfa TGF-β RII and PD-L1 Pre-treated esophageal adenocarcinoma 30 I ORR 20% Anemia, pain NCT02517398 Bintrafusp alfa TGF-β RII and PD-L1 Pre-treated gastric cancer 31 I ORR 22% Anemia, diarrhea, rash NCT02517398 Bintrafusp alfa TGF-β RII and PD-L1 Pre-treated biliary tract cancer 30 I ORR 23% ILD NCT02517398 Bintrafusp alfa TGF-β RII and PD-L1 Refractory colorectal cancer 29 I ORR 3.4% Anemia, fatigue enteritis NCT02631070 Luspatercept ActRIIb IgG1 Very low, low or intermediate risk MDS 229 III Transfusion independent > 8 weeks asthenia, nausea, 38% vs. 13% Fatigue, diarrhea, Antisense nucleotides NCT00431561 Trabedersen vs. Temozolomide/ Lomustine TGF-β2 mRNA Recurrent/ Refractory glioma 142 IIb 6 m tumor control rate: Trabedersen 10uM: 33% Trabedersen 80uM: 20% Chemotherapy: 27% Nervous disorders NCT00844064 Trabedersen TGF-β2 mRNA Advanced tumors known to overproduce TGF-β2 62 I Vaccines NCT01058785 Belagenpumatucel-L TGF-β2 Inhibition NSCLC 75 II ORR 15% Pain, anemia fatigue NCT00676507 Belagenpumatucel-L TGF-β2 Inhibition Inoperable or metastatic NSCLC 532 III mOS 20 vs 17 m Allergic reactions NCT02574533 Vigil + Pembrolizumab Vaccine Anti-PD-1 Advanced melanoma 2 I Summary of completed clinical trials utilizing TGF-β targeting agents in a variety of treatment refractory metastatic solid tumors including breast, esophageal, gastric, biliary, pancreatic, non-small cell lung cancer, melanoma, GBM and head and neck tumors. Nine trials utilized small molecule inhibitors, three utilized antibodies, ten utilized ligand traps, two utilized ASOs, and three utilized vaccination strategies Table 2 Ongoing clinical trials to evaluate TGF-β pathway antagonists in oncology Study NCT Registry Number Agent Target(s) Study Population Number of Patients Phase Clinical status Small molecule receptor kinase inhibitors NCT03724851 Vactosertib + Pembrolizumab TGF-β RI Metastatic CRC, gastric, or GEJC adenocarcinoma 67 Ib/IIa Active, recruiting NCT03732274 Vactosertib + Durvalumab TGF-β RI PD-L1 Advanced NSCLC 63 Ib/IIa Active, recruiting NCT04064190 Vactosertib + Durvalumab TGF-β RI PD-L1 Urothelial cancer 48 II Active, recruiting NCT03143985 Vactosertib + Pomalidomide TGF-β RI IMiD Agent (Cereblon) Relapsed/ Refractory Multiple myeloma 18 Ib/IIa Active, recruiting NCT03698825 Vactosertib + Paclitaxel TGF-β RI Tubulin/ Mitotic spindle Second line therapy for metastatic gastric AC 62 Ib/IIa Active, recruiting NCT04103645 Vactosertib TGF-β RI Anemic, Ph-neg, MPN 37 II Active, not recruiting NCT04258072 Vactosertib naI-IRI/FL TGF-β RI Chemotherapy Metastatic pancreatic Adenocarcinoma 24 Ib/IIa Active, not recruiting NCT03802084 Vactosertib Imatinib TGF-β RI BCR-abl Advanced desmoid tumor 24 Ib/IIa Active recruiting NCT02452008 Galunisertib + Enzalutamide TGF-β RI AR Castration-resistant prostate cancer 60 II Active, recruiting NCT03206177 Galunisertib + Carboplatin/ Paclitaxel TGF-β RI Chemotherapy Ovarian carcinosarcoma 25 I Active, recruiting NCT02688712 Galunisertib + Chemo/RT TGF-β RI Locally advanced rectal cancer II Active, recruiting NCT04031872 LY3200882 Capecitabine TGF-β RI Chemotherapy Advanced Chemotherapy Resistant Colorectal Cancer and an Activated TGF-beta Signature 31 I/II Active, not recruiting Antibodies NCT02581787 Fresolimumab + SBRT TGF-β1, β2, β3 RT Stage Ia/Ib NSCLC 60 I/II Active, not recruiting NCT03192345 SAR438459 + Cemiplimab TGF-β1, β2, β3 PD-L1 Advanced solid tumors 350 I Active, not recruiting NCT04291079 SRK-181 + Anti-PD-L1 TGF-β1 PD-L1 Locally advanced or metastatic solid tumors 183 I First-in-human, dose-escalation, dose expansion study to evaluate safety, tolerability, PK, PD Ligand Traps NCT04349280 Bintrafusp alfa TGF-β RII and PD-L1 Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent 40 Ib Active, recruiting NCT04501094 Bintrafusp alfa TGF-β RII and PD-L1 Checkpoint inhibitor naive urothelial carcinoma 75 II Active, not yet recruiting NCT04066491 Cisplatin/Gemcitabine +/- Bintrafusp alfa Chemotherapy TGF-β RII and PD-L1 First-line Treatment of Biliary Tract Cancer 512 II/III Active, recruiting NCT04220775 SBRT Bintrafusp alfa RT TGF-β RII and PD-L1 Recurrent or Second Primary Head and Neck Squamous Cell Cancer 21 I/II Active, not yet recruiting NCT03833661 Bintrafusp alfa TGF-β RII and PD-L1 Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy 159 II Active, not recruiting NCT03524170 Bintrafusp alfa TGF-β RII and PD-L1 Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer 20 I Active, recruiting NCT04296942 Bintrafusp alfa TGF-β RII and PD-L1 Advanced Stage Breast Cancer (BrEAsT) 65 I Active, recruiting Brachyury-TRICOM Ado-trastuzumab Emtansine Vaccines HER2 HDAC deacetylase NCT03436563 Bintrafusp alfa TGF-β RII and PD-L1 Metastatic colorectal cancer or advanced solid tumors with MSI-high 74 I/II Active, recruiting NCT03840915 Platinum regimen Bintrafusp alfa + and PD-L1 Chemotherapy TGF-β RII Stage IV Non-small Cell Lung Cancer 70 Ib/II Active, not recruiting NCT03840902 Chemo-RT Bintrafusp alfa + Chemo-RT TGF-β RII Unresectable Stage III Non-small Cell Lung Cancer. Bintrafusp alfa with concurrent chemoradiation followed by bintrafusp vs. concurrent chemoradiation + placebo followed by durvalumab 350 III Active, recruiting Vaccines NCT02346747 Vigil Vaccine Stage IIIb, IIIc, IV high-grade papillary, serous, clear cell, serous ovarian cancer. 91 II Active, not recruiting NCT03073525 Vigil Atezolizumab Vaccine PD-L1 Stage IIIb, IV ovarian cancer. Patients had tumor harvested at surgery and successful manufacturing of Vigil but were ineligible for CL-PTL-119 (the VITAL study) or previously randomized to placebo. 25 II Active, not recruiting NCT02725489 Vigil Durvalumab Vaccine PD-L1 Advanced Women’s cancers. Confirmed diagnosis of women's cancer, inclusive, but not limited to breast, ovarian, fallopian tube, primary peritoneal, uterine, cervical, endometrial, that is locally advanced or metastatic for which the projected response rate to durvalumab is 15% or less. 13 II Active, not recruiting NCT02511132 Vigil Vaccine Metastatic Ewing's sarcoma refractory or intolerant to at least 1 prior line of systemic chemotherapy. 22 IIb Active, not recruiting vs. Gem/docetaxel Chemotherapy (Part A) + Temozolomide/ Irinotecan II (Part B) NCT03842865 Vigil Vaccine Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors including Ewing's sarcoma, Ewing's tumor metastatic, Ewing's sarcoma metastatic, advanced gynecological cancers, ovarian, cervical, and uterine cancers. 40 Expanded Access Temporarily not available Summary of ongoing clinical trials that are utilizing TGF-β targeting agents in solid tumor as well as hematological malignancies including MM and MPNs. Twelve trials utilized small molecule inhibitors, three utilized antibodies, nine utilized ligand traps, and five utilized vaccination strategies

Small molecule inhibitors of TGF-β receptor kinase activity

Several TGF-β R kinase inhibitors have been designed to bind the ATP-binding domain of TGF-β R kinase and inhibit ATP kinase activity and block the downstream signaling cascade [ 66 , 67 ].

Vactosertib (TEW-7197, MedPacto) is an orally available inhibitor of the kinase activity of TGF-β RI/ALK-5 (IC 50 = 12.9 nM) [ 68 , 69 ]. Vactosertib also inhibits ALK-2 and ALK-4 with an IC 50 value of 17.3 nM. In murine models, Vactosertib limits the growth and suppresses progression of many solid tumor types and as well as the plasma cell neoplasm MM. Mechanistically, Vactosertib acts pleiotropically on multiple cell types through tumor intrinsic and extrinsic mechanisms (Fig. 3 ). The safety and efficacy of Vactosertib against a number of different cancer types have been reported in a number of completed trials (Table 1 ). Fig. 3 Tumor Intrinsic and Extrinsic Effects of Vactosertib. Vactosertib exerts potent antitumor effects (indicated in red) directly on cancer cells as well as on a number of other cell types

A first-in-human phase I dose escalation study investigated the safety, tolerability and pharmacokinetics of Vactosertib in patients with advanced, refractory solid tumors ( NCT02160106 ) [ 70 , 71 ]. Vactosertib pharmacokinetics were dose proportional when administered once daily for five days. Based upon a relatively short half-life, it was postulated that Vactosertib should be administered twice or thrice daily to maintain a concentration above a minimum effective level over dosing interval. A two-compartment linear model with first-order absorption and absorption lag time adequately described the population pharmacokinetics [ 70 ].

An open-label, multi-center study assessed the safety, tolerability, pharmacokinetics and antitumor activity of Vactosertib in combination with Pembrolizumab (Keytruda, Merck) in patients with either metastatic colorectal or gastric cancer or gastroesophageal junction adenocarcinoma ( NCT03724851 , [ 72 ]). Study results indicated objective response rates (ORRs) of 16.7% and 33.3%, respectively, for colon cancer patients who failed entire body anticancer treatment based on RECIST and iRECIST (primary and secondary anticancer evaluation indices). Colon cancer patients who participated in clinical tests demonstrated a microsatellite stable genotype, which previously had a non-existent objective response rate with pembrolizumab alone. A decrease in the colon cancer tumor marker CEA value was observed in half of the patients that received Vactosertib and suggested that tumor was effectively reduced in patients as treatment continued.

Combined inhibition of immune checkpoint and TGF-β signaling is a promising therapeutic strategy since these key pathways have independent but complementary immunosuppressive functions. Safety and efficacy of Vactosertib combined with Durvalumab (Imfinzi, Medimmune, AstraZeneca), a human mAb directed against programmed death-ligand 1 (PD-L1), was evaluated in patients with metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma ( NCT03732274 , [ 73 ]). The trial was conducted on 15 NSCLC patients and a 16.7% ORR was observed, even though patients demonstrated < 25% of PD-L1 expression in tumors. Importantly, imfinzi monotherapy demonstrated an ORR of 2.8% clinical test conducted on the same patient group. A phase II, open-level, non-randomized single-arm study will determine whether the administration of Vactosertib with Durvalumab increased the overall response rate in patients with urothelial cancers that fail to achieve a CR with anti-PD-1/PD-L1-based regimens ( NCT04064190 ). The combination of Vactosertib plus Durvalumab is well-tolerated and without safety concerns.

A phase II study will determine the recommended dose and evaluate the safety of Vactosertib in combination with nanoliposomal irinotecan (NaI-IRI) with 5-FU and leucovorin (FL) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine (GEM) and nab-paclitaxel ( NCT04258072 ). A phase I/II, open-label, non-randomized, multicenter study will evaluate the clinical activity of Vactosertib plus Imatinib in desmoid tumors ( NCT03802084 ). Based upon impressive preclinical and translational studies, Vactosertib has been combined with the immunomodulatory agent Pomalidomide (Pom, Pomalyst, Bristol-Myers Squibb) in a phase Ib/IIa study to treat participants with relapsed and/or refractory MM ( NCT03143985 ) [ 74 , 75 ]. Results indicated that the combination was safe and that progression-free survival (PFS) was 80%, higher than historical controls seen with Pom alone (PFS = 20%) or that seen with Pom and corticosteroids (PFS = 40%).

A dose escalation, proof-of-concept study of Vactosertib monotherapy in patients with myelodysplastic syndromes (MDS) has also been reported ( NCT03074006 ). A prospective, open-label, multicenter, phase I/II study of Vactosertib in patients with low and intermediate risk of MDS evaluated hematological improvement, maximum tolerated dose, bone marrow response and quality of life. Preclinical and clinical results indicated that TGF-β1 levels were increased in subset of MDS samples and Vactosertib treatment led to reversal of hematopoietic alteration upon exposure to MDS serum in vitro and increased blood counts in vivo [ 76 , 77 ].

A two-tiered, single-arm, phase II trial of Vactosertib for anemic myeloproliferative neoplasm (MPN) patients was recently designed ( NCT04103645 ) and will assess how well Vactosertib works in MPN patients to improve anemia and provide new information about how this agent blocks TGF-β signaling in MPN cells. In turn, the study will determine whether Vactosertib can block MPN cells and their effects on bone marrow, e.g., fibrosis.

An open-labeled, multicenter phase Ib/IIa, single-arm study was designed to evaluate the safety and tolerability of Vactosertib in combination with weekly paclitaxel as second-line treatment for metastatic gastric adenocarcinoma patients ( NCT03698825 ). A report is that paclitaxel (Taxol; Bristol-Myers Squibb Co.) significantly suppressed the TGF-β /Smad signaling pathway by inhibiting Smad2 phosphorylation in the peritoneum [ 78 ]. A multi-center, open-label, phase Ib clinical was designed to evaluate the safety, tolerability and exploratory efficacy of Vactosertib in combination with FOLFOX in patients with PDAC who failed first-line GEM and nab-Paclitaxel ( NCT03666832 ).

Galunisertib (LY21557299, Eli Lilly & Co.) is a TGF-βRI kinase inhibitor that has been shown to reduce the growth of lung and breast cell lines and was safe in patients with various solid tumors in phase I studies [ 79 – 81 ]. In a phase II study of galunisertib in combination with lomustine, compared to lomustine with placebo, in patients with recurrent glioma failed to demonstrate improved OS relative to placebo plus lomustine ( NCT01582269 ). In a separate phase II study, 40 patients with hepatocellular carcinoma (HCC) that had progressed on or were ineligible to receive sorafenib (Bayer, Onyx) were treated with intermittent dosing of galunisertib (14 days on/14 days off) [ 82 ]. HCC patients with normal α-fetoprotein and with TGF-β1 reduction improved in OS compared to patients with non-TGF-β1 reduction ( NCT01246986 ). In a phase II study of patients with unresectable pancreatic cancer, patients treated with galunisertib in combination with GEM improved OS (10.9 vs. 7.2 months) compared to those treated with GEM and placebo ( NCT01373164 ).

The incentive to move galunisertib forward was based largely on the development of an intermittent dosing schedule by predictive pharmacology, pharmacodynamic markers and preclinical toxicology models [ 83 ]. The optimal effective dosing schedule that can induce antitumor activity, but lacks cardiac toxicity, consists of iterative cycles (28 days/cycle) comprised of two-week treatment with galunisertib followed by two weeks without drug. The protocol was applied to patients with glioma, and serious cardiac toxicity was not observed [ 84 ]. In metastatic PDAC, targeting TGF-β signaling could be a rational approach since it is involved in tumor progression and has been associated with poor prognosis [ 85 ]. A randomized phase II study assigned 156 patients to receive galunisertib plus GEM or placebo plus GEM in stage II-IV unresectable PDAC. The combination of galunisertib and GEM resulted in improved OS and PFS and a manageable toxicity profile compared to that of placebo and GEM [ 85 , 86 ].

LY3200882 (Eli Lilly) is a next-generation, potent and highly selective ATP competitive inhibitor of the TGF-βRI serine-threonine kinase domain [ 87 ]. In a multicenter, non-randomized, open-label study, dose-escalation study of LY3200882 monotherapy, the recommended phase II dose was established at 50 mg bid at two weeks on/two weeks off for patients with advanced or metastatic cancers were treated with ( NCT02937272 ) [ 88 ]. Five cohorts of patients with advanced or metastatic cancer following progression on standard therapy received LY3200882 twice daily at increasing doses. Tumor types included were glioma ( n = 15), GBM ( n = 5), pancreatic ( n = 3), cervical ( n = 3), chondrosarcoma ( n = 2), appendiceal ( n = 1) and colorectal adenocarcinoma ( n = 1). Findings showed that a twice-daily dose of 50 mg at two week-on/two week-off schedule was optimal. Moreover, dose-limiting toxicities were not observed, and all treatment-related adverse events were of grade 1 or 2. Across all cohorts, there was one partial response in the 50 mg cohort—six cases of stable disease, 11 with progressive disease and 12 with non-evaluable disease. The overall response rate (ORR) was 3.3% ( n = 1), and disease-control rate was 23.3% ( n = 7). Additionally, an 85.7% tumor reduction, assessed by response assessment in neuro-oncology criteria, was reported in one patient with EGFR-mutant, CDK4-amplified, IDH1/2 wild-type and MGMT-methylated GBM. The patient was treated at 50 mg bid and has remained on treatment for more than 11 months.

LY573636 (Tasisulam, Eli Lilly) LY573636 is a TGF-β RI inhibitor that exhibited broad spectrum of preclinical antitumor activity [ 89 ]. LY573636 was evaluated in a phase I dose-escalation study in patients with advanced or refractory solid tumors. The primary objective was to determine the recommended phase II dose of tasisulam; secondary objectives were to characterize the toxicity and pharmacokinetic profiles of tasisulam and to discern whether there was any antitumor activity [ 89 ]. Twenty-six patients were enrolled. No dose-limiting toxicities (DLTs) were observed until cohort 3 (grade 3 hyperbilirubinemia). Interim PK analyses of this and another ongoing phase I study suggested that a lower dose after cycle 1 was necessary for doses ≥ 2,500 mg because of the long half-life of tasisulam (~ 14 days). When administered as a flat-dose, 24-h infusion, the MTD of drug was a loading dose of 2,500 mg followed by a chronic dose of 1,750 mg, every 28 days. Consistent with the profile of the two-hour infusion in clinical development, bone marrow suppression was the major DLT.

A83-01 is a small molecule TGF-β RI/ALK-5 kinase inhibitor with an IC 50 of 12 nM [ 90 ]. Aberrant hepatic growth factor (HGF)/c-MET upregulation and activation is frequently observed in bladder cancer correlating with cancer progression and invasion. However, the mechanisms underlying HGF/c-MET-mediated invasion in bladder cancer remain poorly defined. As part of a negative feedback loop, SMAD7 binds SMURF2 targeting the TGF-β receptor for degradation. SMAD7 then acts as a SMURF2 agonist by disrupting interactions within SMURF2. Recently, Sim et al. showed that HGF stimulates TGF-β signaling through c-SRC-mediated phosphorylation of SMURF2 resulting in loss of SMAD7 binding and enhanced SMURF2 C2-HECT interaction that inhibits SMURF2 and enhances TGF-βR stabilization [ 91 ].

LY2109761 (Eli Lilly) is an orally active, selective TGF-βRI/II inhibitor with Ki values of 38 nM and 300 nM, respectively [ 92 ]. It is metabolically stable and suitable for in vivo studies. The efficacy of LY2109761 on tumor growth, survival and reduction of metastasis was evaluated in an orthotopic murine model of pancreatic cancer. LY2109761, in combination with GEM, significantly reduced tumor burden, prolonged survival and reduced spontaneous abdominal metastases [ 93 ].

LY364937 (Eli Lilly), Ki26894 (Kirin Brewery Company). Treatment with the TGF-βRI/ALK-5 inhibitor LY364937 led to a reduction in formation of early bone and lung metastases in a MDA-MB-435-F-L orthotopic xenograft model into nude mice [ 94 ]. Ki26894 is another TGF-β type I receptor kinase inhibitor that has shown efficacy against breast and gastric cell lines and xenografts in a mouse cancer model [ 95 , 96 ].

LY580276 (Eli Lilly) has been shown to block EMT and tumor cell migration in pancreatic cancer and mouse mammary epithelial cells, respectively [ 97 , 98 ].

SB-431542 and SB-505124 (GlaxoSmithKline) are noteworthy TGF-β R kinase inhibitors in pre-clinical development. These TGF-β RI inhibitors block Smad2/3 phosphorylation. The expression of c-myc, which is downregulated by TGF-β in many cell types, was upregulated in MG63 human osteosarcoma cells, suggesting that upregulation of c-myc expression meay be the mechanism of blocking growth suppressing signals in of TGF-β in MG63 cells [ 99 ]. Inhibitors for a TGF-β type I receptor kinase, SB-431542 and Ki26894, potently enhanced osteoblast differentiation from bone marrow stromal cells as well as MC3T3-E1 cells. The TGF-β inhibition was able to restore osteoblast differentiation suppressed by MM cell conditioned medium as well as bone marrow plasma from MM patients [ 100 ]. However, these inhibitors are not specific, are relatively unstable and generate unpredictable outcomes with unwanted, adverse side effects.

SD-093 and SD-208 are also in pre-clinical development and exhibit antimetastatic effects against gliomas and melanomas [ 101 , 102 ] and blocked EMT and tumor cell migration in pancreatic cancer [ 103 ].

IN-1130 (In2Gen) that also inhibits TGF-βRI, ALK-4 and ALK-7 signaling decreased tumor growth of prostate cancer xenografts in mice and [ 104 ] and inhibited lung metastasis of breast cancer and increased overall survival (OS) of the mice [ 105 ].

TGF-β-directed antibodies to block ligand activation or prevent ligand receptor binding

Antibodies are used to interfere with TGF-β ligand binding to its cognate receptor as well as to block activation of latent TGF-β. Both steps are critical for TGF-β to elicit its pro-tumorigenic and immune suppressive responses.

SRK181-mIgG1 (Scholar Rock). Cancer immunotherapy, including immune checkpoint blockade, has achieved increased prominence in the recent years [ 65 ]. Despite breakthroughs achieved with cancer checkpoint therapy, only a fraction of patients respond to anti-PD-1 therapy because of primary or secondary (acquired) resistance. Studies have suggested that inhibition of TGF-β may help overcome resistance to immune checkpoint blockade ( NCT04291079 ). Conventional TGF-β antagonists do not discriminate among the three isoforms of TGF-β. It was reasoned that a lack of isoform selectivity may underlie the toxicities observed in both preclinical and human studies. To achieve improved safety and a therapeutic window enabling higher dosing, antibodies were designed and aimed at selectively targeting the latent TGF-β1 complex, without meaningfully affecting other isoforms. Retrospective analyses of clinical tumor samples identified TGF-β1 as the most prevalent TGF-β isoform in solid cancers. Preclinical results demonstrated that the highly selective inhibition of TGF-β1 activation with SRK 181-mIgG1 overcame primary resistance to checkpoint inhibitors. SRK181-mIgG1 is a potent and highly selective inhibitor of the TGF-β1 isoform and is an investigational product candidate being developed to overcome primary resistance to checkpoint inhibitor therapy, such as anti-PD-(L)1 Abs. Results demonstrated the effectiveness and safety of the agent with immune checkpoint blockade in mouse cancer models.

Fresolimumab (GC1008, Genzyme) is a human mAb that neutralizes TGF-β1 and TGF-β2 that was tested in a phase I trial of 28 patients with malignant melanoma and one patient with RCC. Seven patients showed partial response, four developed reversible cutaneous keratoacanthomas and SCCs, and one patient acquired hyperkeratosis as unwanted side effects [ 106 ].

LY3022859 (Eli Lilly), an anti-TGF-βRII mAb, inhibits receptor-mediated TGF-β signaling activation and was tested in a phase I trial composed of 14 patients with advanced solid tumors. The maximum dose tolerance was not determined. Dose escalation beyond 25 mg/dose was considered unsafe due to negative symptoms, e.g., uncontrolled cytokine release, despite prophylaxis. Unfortunately, a safe dose at which the drug was active was not determined [ 107 ].

264RAD (AstraZeneca) is a human mAb that targets αvβ6 integrin that has a key role in activation of latent TGF-β, has been shown to reduce tumor growth and metastasis in vivo [ 108 , 109 ]. Targeting αvβ6 with 264RAD antibody alone or combined with trastuzumab (Herceptin, Genentech), a human epidermal growth factor receptor 2 (EGFR) neutralizing Ab, can benefit patients with high-risk, trastuzumab-resistant disease [ 110 ].

1D11 (Genzyme Corp., Sanofi) binds TGF-β1, 2 and 3, which suppresses lung metastasis in a breast cancer mouse model, by increasing in the antitumor response of CD8 + T cells [ 111 ].

2G7 (Genentech) is a second mAb that has shown efficacy in preclinical trials to inhibit breast cancer metastasis by increasing NK cell activity [ 112 , 113 ].

TGF-β ligand traps

AVID200 (BMS) is an engineered TGF-β ligand trap comprised of TGF-βR ectodomains fused to a human Fc domain. AVID200 has antibody-like properties and is 1,000 times more selective for neutralizing TGF-β1 and TGF-β3, compared to TGF-β2 [ 114 ]. AVID200 does not target TGF-β2, which is a positive regulator of hematopoiesis and normal cardiac function, and blockade of TGF-β2 is undesirable. Since TGF-β1 and TGF-β3 are negative regulators of hematopoiesis, while TGF-β2 is a positive regulator of hematopoiesis, the unique isoform selectivity profile of AVID200 makes it an attractive agent for the treatment of MDS-associated anemia. The ability of AVID200 to selectively target TGF-β1 and TGF-β3 positions it to be an effective and well-tolerated therapeutic in oncology.

Bintrafusp alfa (GSK-4045154, M7824, MSB0011359C, EMD Serono/GlaxoSmithKline/ Merck KGaA) is an innovative first-in-class bifunctional fusion protein composed of a mAb against PD-L1 fused to the extracellular domain of the TGF-β receptor II [ 115 ]. In the 3 + 3 dose-escalation component of phase I study ( NCT02517398 ), eligible patients with advanced solid tumors received Bintrafusp alfa once every 2 weeks until confirmed progression, unacceptable toxicity or trial withdrawal. Bintrafusp alfa demonstrated manageable safety profile in patients with heavily pre-treated advanced solid tumors. A phase 1, open-label trial included 80 patients with advanced NSCLC that progressed after platinum doublet therapy or platinum-based adjuvant or neoadjuvant treatment and those who also had not received previous immunotherapy. Patients were randomized at a one-to-one ratio to receive Bintrafusp alfa 500 mg or the recommended phase 2 dosage of 1200 mg every 2 weeks [ 116 ]. Bintrafusp alfa had encouraging efficacy and manageable tolerability in platinum-treated NSCLC patients. While pembrolizumab received accelerated FDA approval based upon ORR and duration of response (DOR) for patients with recurrent/metastatic cervical cancer with tumors that express PD-L1, the ORR of 14.3% suggests that there remains a significant unmet need for patients with previously treated advanced cervical cancer unselected for PD-L1. A multi-center, global single-arm phase II study ( NCT04246489 ) will assess the clinical activity and safety profile of Bintrafusp alfa in platinum-experienced cervical cancer [ 117 ].

Luspatercept (Luspatercept-aamt, Acceleron) is a first-in-class erythroid maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. It is a recombinant fusion protein derived from human activin receptor type IIb (ActRIIb) linked to a protein derived from IgG. Luspatercept binds TGF-β ligands to reduce SMAD2 and SMAD3 signaling. Luspatercept was shown to reduce the severity of anemia in patients with lower-risk MDS with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to erythropoiesis-stimulating agents or who had discontinued such agents [ 118 ].

Soluble TGFβRII (sTGF-βRII)-Fc and soluble betaglycan (sBetaglycan)-Fc were constructed as Fc fusion proteins, in which immunoglobulin fragment crystallizable (Fc) was fused to the extracellular domain of TGF-βRII and betaglycan, respectively [ 119 ]. In a manner similar to that of neutralizing antibodies, targeting TGF-β with sTGF-βRII-Fc and sBetaglycan-Fc also reduced tumor growth and metastasis in preclinical models. TβRII-Fc was shown to induce apoptosis in primary tumors and reduced tumor cell motility, intravasation and lung metastases from transplanted 4T1 and EMT-6 mammary tumors in syngeneic mice [ 120 ].

ASOs targeting the TGF-β pathway

Antisense oligonucleotides (ASOs) offer a novel approach to specifically target and inactivate genes involved in cancer progression, especially those that are difficult to inhibit by small molecules or mAbs [ 121 ]. Due to their instability, nanoparticles and chemically modified ASOs have been developed to improve delivery and stability of oligonucleotides to target cells or tissues [ 122 , 123 ].

AP12009 (Trabedersen, Antisense Pharma GmbH/Isarna) targets TGF-β2 expression and is being studied to treat malignant glioma, pancreatic carcinoma and malignant melanoma with an immunotherapy approach. After providing preclinical proof-of-concept results, the safety and efficacy of AP12009 were assessed in an open-label phase I/II dose-escalation study for recurrent and/or refractory high-grade glioma patients [ 124 , 125 ]. Median survival time after recurrence exceeded the current literature data for chemotherapy. AP12009 has undergone or is currently use in phase III trials against astrocytoma ( NCT00761280 ).

AP11014 and AP15012 are antisense molecules used in pre-clinical trials for treatment of non-small cell lung cancer, prostate carcinoma, CRC and MM, respectively [ 56 , 126 ].

Vaccine-based approaches to modulate TGF-β signaling

Vigil (Vital, Gradalis) is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding the gene for the immune-stimulatory cytokine GM-CSF, and a bifunctional short hairpin RNA (shRNA) which specifically knocks down expression of furin, a critical convertase responsible for production of TGF-β1 and TGF-β2. GM-CSF enhances surface antigen expression, making cancer cells more visible to the patient’s immune system and further stimulates the immune system by recruiting and maturing antigen-presenting cells, e.g., DCs. Vigil (Vital) is being investigated as a maintenance therapy in patients with high-risk stage 3b-4 ovarian cancer in a multicenter, randomized, double-blind, placebo-controlled, phase II/III trial ( NCT02346747 ). The study involves more than 80 patients diagnosed with stage 3B, 3C or 4 high-grade papillary serous/clear cell/endometrioid ovarian, fallopian tube or primary peritoneal cancer. Patients were randomized to receive either vigil or placebo, and the primary goal is to determine patients’ recurrence-free survival (RFS) and overall survival (OS). Phase II of Vital in 42 cancer patients that demonstrated that Vigil is safe, leads to T-cell activation and improves RFS [ 127 ].

Another phase II crossover study ( NCT03073525 ) is evaluating the safety and antitumor activity of vigil in women diagnosed with advanced gynecological cancers, e.g., ovarian, cervical and uterine. Vigil’s safety and antitumor activity, in combination with the immune checkpoint inhibitor atezolizumab (Tecentriq, Genentech), are being evaluated. Biomarkers are being used to measure antitumor systemic immune response generated either by Vigil alone, atezolizumab alone or the combination of the agents.

A pilot study ( NCT02725489 ) is evaluating the safety, tolerability and efficacy of the combination of Vigil immunotherapy, and durvalumab (Imfinzi), a PD-L1 inhibitor, in women diagnosed with different types of advanced breast, ovarian, cervical, uterine, fallopian, primary peritoneal and endometrial cancer is recruiting patients. The main purpose of the study is to investigate the effects the combination treatment may have on patients, and whether or not the combination helps in slowing down the progression of the disease. An open-label pilot study ( NCT02574533 ) examined the combination of vigil and pembrolizumab in inducing cancer-specific T-cell immunity in patients with incurable locally advanced or metastatic melanoma. Pembrolizumab is a humanized mAb which activates T-cell-mediated immune responses against tumor cells. The safety of vigil immunotherapy in combination with other drugs is also being evaluated in phase IIb trial ( NCT02511132 ) involving patients with metastatic Ewing’s sarcoma that could not be treated with at least one prior line of systemic chemotherapy. Finally, a multicenter, expanded access protocol of intradermal autologous vigil in solid tumor patients is ongoing ( NCT03842865 ).

Belagenpumatucel-L (Lucanix, NovaRx Corp.) was prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-β2 antisense transgene [ 128 ]. Patients that received belagenpumatucel-L had a dose-related survival advantage ( NCT00676507 ) [ 129 ]. Tumor cells promote immunosuppressive Treg cell proliferation directly through TGF-β production or by DC conversion into regulatory cells that secrete TGF-β. TGF-β2 antagonizes natural killer (NK) cells, lymphokine-activated killer cells, and DC function and belagenpumatucel-L reduced TGF-β2-mediated immunosuppression [ 130 – 134 ].

Shortcomings of TGF-β antagonists

The dual role of TGF-β in cancer highlights the need to better understand the contextual effects of this cytokine to better guide patient selection for the use of anti-TGF-β therapies in oncology. Furthermore, TGF-β is secreted by nearly every cell type, is therefore ubiquitous and regulates numerous critical physiologic processes in healthy cells. Limited mechanistic understanding of the dual, opposing actions of TGF-β as a tumor suppressor and tumor promoter remains a challenge in the development of TGF-β antagonists as cancer therapy. Combined with the pleiotropic activities of TGF-β and the lack of biomarkers, patient selection criteria and optimal dosing regimens are yet to be determined. However, many of these agents have limited activity when given as monotherapy, effective combinations with other anticancer strategies, e.g., immunotherapy, checkpoint inhibitors. Moreover, molecular biomarkers to stratify patient selection and treatment decisions are only beginning to emerge. Future clinical trials that incorporate bioinformatic tools and define biomarkers that identify patients who would benefit from TGF-β therapy are needed to advance the incorporation of TGF-β receptor antagonists into frontline cancer treatment.

Conclusions

A number of TGF-β pathway antagonists have advanced to clinical trials and demonstrated acceptable safety profiles and significant therapeutic efficacy in cancer patients. Vactosertib, in combination with chemotherapy and immunotherapeutics, has been well tolerated and shown promising activity against a number of cancer types. AVID200 was safe, well tolerated with peripheral target engagement across the entire dosing period and led to TGF-β target modulation and immune activation. Bintrafusp alfa, the first-in-class bifunctional fusion protein TGF-β trap fused to a human immunoglobulin G1 antibody blocking PD-L1, had encouraging efficacy and manageable tolerability in patients with NSCLC previously treated with platinum. We conclude that TGF-β pathway antagonists, in combination with other modalities, are highly relevant since they provide a rapidly acting, cost-effective and feasible approach to improve cancer treatment. In addition, TGF-β pathway antagonists serve as a reasonable option for patients resistant to conventional therapies. While challenges remain, perspectives are enhanced by recently completed and ongoing clinical trials.

Abbreviations

activin receptor-like kinase

antisense oligonucleotides

bone morphogenic protein

cyclin-dependent kinase

cancer stem cells

cytotoxic T lymphocyte antigen-4

dendritic cell

dose-limiting toxicity

epithelial to mesenchymal transition

epithelial growth factor receptor

fragment crystallizable

glioblastoma multiforme

granulocyte macrophage colony-stimulating factor

glioma-initiating cells

non-small cell lung cancer

overall response rate

myeloid-derived suppressor cells.

myeloproliferative neoplasm

multiple myeloma

myelodysplastic syndrome

natural killer

overall survival

pancreatic ductal adenocarcinoma

progression-free survival

programmed death ligand 1

Response Evaluation Criteria in Solid Tumors

recurrence-free survival

Caenorhabditis elegans Sma genes and the Drosophila mothers against decapentaplegic proteins

transforming growth factor beta

T helper

regulatory T cell

tyrosine kinase inhibitor

tumor microenvironment

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Not applicable.

Authors' contributions

JD and BGK wrote the initial draft. BGK, EM, SHC, JIH and JD edited the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors gave consent for publication of the manuscript.

Competing interests

All other authors declare no competing interests.

References

1. Moses HL Roberts AB Derynck R The discovery and early days of TGF-beta: a historical perspective Cold Spring Harb Perspect Biol. 2016 8 7 021865 10.1101/cshperspect.a021865 PMC4930926 27328871

2. Massague J TGFbeta in cancer Cell 2008 134 2 215 230 18662538 10.1016/j.cell.2008.07.001 PMC3512574

3. Moustakas A Heldin CH The regulation of TGF beta signal transduction Development 2009 136 22 3699 3714 19855013 10.1242/dev.030338

4. Massague J TGF beta signalling in context Nat Rev Mol Cell Biol 2012 13 10 616 630 22992590 10.1038/nrm3434 PMC4027049

5. Batlle E Massague J Transforming growth factor-beta signaling in immunity and cancer Immunity 2019 50 4 924 940 30995507 10.1016/j.immuni.2019.03.024 PMC7507121

6. Heldin CH Moustakas A Signaling receptors for TGF-beta family members Csh Perspect Biol. 2016 8 8 022053 10.1101/cshperspect.a022053 PMC4968163 27481709

7. Tzavlaki K Moustakas A TGF-beta signaling Biomolecules 2020 10 3 487 10.3390/biom10030487 PMC7175140 32210029

8. Smith AL Robin TP Ford HL Molecular pathways: targeting the TGF-beta pathway for cancer therapy Clin Cancer Res 2012 18 17 4514 4521 22711703 10.1158/1078-0432.CCR-11-3224

9. Blobe GC Schiemann WP Lodish HF Role of transforming growth factor beta in human disease N Engl J Med 2000 342 18 1350 1358 10793168 10.1056/NEJM200005043421807

10. Bhowmick NA Chytil A Plieth D Gorska AE Dumont N Shappell S Washington MK Neilson EG Moses HL TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 2004 303 5659 848 851 14764882 10.1126/science.1090922

11. Ikushima H Miyazono K TGFβ signaling: a complex web in cancer progression Nat Rev Cancer 2010 10 415 424 20495575 10.1038/nrc2853

12. Tang J Gifford CC Samarakoon R Higgins PJ Deregulation of negative controls on TGF-β1 signaling in tumor progression Cancers (Basel) 2018 10 6 159 10.3390/cancers10060159.PMID:29799477;PMCID:PMC6025439 PMC6025439 29799477

13. Boulay J-L Mild G Lowy A Reuter J Lagrange M Terracciano L Laffer U Herrmann R Rochlitz C SMAD7 is a prognostic marker in patients with colorectal cancer Int J Cancer 2003 104 446 449 12584741 10.1002/ijc.10908

14. Tang J Gifford CC Samarakoon R Higgins PJ Deregulation of negative controls on TGF-β1 signaling in tumor progression Cancers 2018 10 159 10.3390/cancers10060159 PMC6025439 29799477

15. Lindley LE Briegel KJ Molecular characterization of TGF beta-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells Biochem Bioph Res Commun 2010 399 4 659 664 10.1016/j.bbrc.2010.07.138 20691661

16. Giampieri S Pinner S Sahai E Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis Can Res 2010 70 9 3435 3439 10.1158/0008-5472.CAN-10-0466 PMC2883737 20424121

17. Yang L Pang YL Moses HL TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression Trends Immunol 2010 31 6 220 227 20538542 10.1016/j.it.2010.04.002 PMC2891151

18. Dahmani A Delisle JS TGF-beta in T cell biology: implications for cancer immunotherapy Cancers. 2018 10 6 194 10.3390/cancers10060194 PMC6025055 29891791

19. Gorelik L Flavell RA Transforming growth factor-beta in T-cell biology Nat Rev Immunol 2002 2 1 46 53 11905837 10.1038/nri704

20. Massague J How cells read TGF-beta signals Nat Rev Mol Cell Biol 2000 1 3 169 178 11252892 10.1038/35043051

21. Sad S Mosmann TR Single Il-2-secreting precursor Cd4 T-cell can develop into either Th1 or Th2 cytokine secretion phenotype J Immunol 1994 153 8 3514 3522 7930573

22. Gorelik L Flavell RA Abrogation of TGF-β signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease Immunity 2000 12 2 171 181 10714683 10.1016/s1074-7613(00)80170-3

23. Wolfraim LA Walz TM James Z Fernandez T Letterio JJ p21(Cip1) and p27(Kip1) act in synergy to alter the sensitivity of naive T cells to TGF-beta-mediated G(1) arrest through modulation of IL-2 responsiveness J Immunol 2004 173 5 3093 3102 15322169 10.4049/jimmunol.173.5.3093

24. Sledzinska A Hemmers S Mair F Gorka O Ruland J Fairbairn L Nissler A Muller W Waisman A Becher B TGF-beta signalling is required for CD4(+) T cell homeostasis but dispensable for regulatory T cell function Plos Biol. 2013 11 10 1001694 10.1371/journal.pbio.1001674 PMC3792861 24115907

25. Thomas DA Massague J TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 2005 8 5 369 380 16286245 10.1016/j.ccr.2005.10.012

26. Donkor MK Sarkar A Savage PA Franklin RA Johnson LK Jungbluth AA Allison JP Li MO T Cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta 1 cytokine Immunity 2011 35 1 123 134 21757379 10.1016/j.immuni.2011.04.019 PMC3430371

27. Ahmadzadeh M Rosenberg SA TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells J Immunol 2005 174 9 5215 5223 15843517 10.4049/jimmunol.174.9.5215 PMC2562293

28. Yoon JH Jung SM Park SH Kato M Yamashita T Lee IK Sudo K Nakae S Han JS Kim OH Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes EMBO Mol Med 2013 5 11 1720 1739 24127404 10.1002/emmm.201302524 PMC3840488

29. Chen WJ Jin WW Hardegen N Lei KJ Li L Marinos N McGrady G Wahl SM Conversion of peripheral CD4(+)CD25(-) naive T cells to CD4(+)CD25(+) regulatory T cells by TGF-beta induction of transcription factor Foxp3 J Exp Med 2003 198 12 1875 1886 14676299 10.1084/jem.20030152 PMC2194145

30. Fantini MC Becker C Monteleone G Pallone F Galle PR Neurath MF Cutting edge: TGF-beta induces a regulatory phenotype in CD4(+)CD25(-) T cells through Foxp3 induction and down-regulation of Smad7 J Immunol 2004 172 9 5149 5153 15100250 10.4049/jimmunol.172.9.5149

31. Chen ML Pittet MJ Gorelik L Flavell RA Weissleder R von Boehmer H Khazaie K Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo Proc Natl Acad Sci USA 2005 102 2 419 424 15623559 10.1073/pnas.0408197102 PMC544311

32. Takimoto T Wakabayashi Y Sekiya T Inoue N Morita R Ichiyama K Takahashi R Asakawa M Muto G Mori T Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development J Immunol 2010 185 2 842 855 20548029 10.4049/jimmunol.0904100

33. Laouar Y Sutterwala FS Gorelik L Flavell RA Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma Nat Immunol 2005 6 6 600 607 15852008 10.1038/ni1197

34. Yu JH Wei M Becknell B Trotta R Liu SJ Boyd Z Jaung MS Blaser BW Sun J Benson DM Pro- and antiinflammatory cytokine signaling: Reciprocal antagonism regulates interferon-gamma production by human natural killer cells Immunity 2006 24 5 575 590 16713975 10.1016/j.immuni.2006.03.016

35. Castriconi R Cantoni C Della Chiesa M Vitale M Marcenaro E Conte R Biassoni R Bottino C Moretta L Moretta A Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells Proc Natl Acad Sci USA 2003 100 7 4120 4125 12646700 10.1073/pnas.0730640100 PMC153058

36. Crane CA Han SJ Barry JJ Ahn BJ Lanier LL Parsa AT TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8(+) T cells glioma patients Neuro Oncol 2010 12 1 7 13 20150362 10.1093/neuonc/nop009 PMC2940557

37. Lee JC Ahn YO Kim DW Heo DS Elevated TGF-b1 secretion and downmodulation of NKG2D underlies impaired NK cytotoxicity in cancer patients J Immunother 2004 27 6 50 10.4049/jimmunol.172.12.7335 15187109

38. Ramalingam R Larmonier CB Thurston RD Midura-Kiela MT Zheng SG Ghishan FK Kiela PR Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity J Immunol 2012 189 8 3878 3893 22972928 10.4049/jimmunol.1201029 PMC3466393

39. Dumitriu IE Dunbar DR Howie SE Sethi T Gregory CD Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4(+)CD25(+)Foxp3(+) regulatory T cells J Immunol 2009 182 5 2795 2807 19234174 10.4049/jimmunol.0712671

40. Papaspyridonos M Matei I Huang YJ Andre MD Brazier-Mitouart H Waite JC Chan AS Kalter J Ramos I Wu Q Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation Nat Commun 2015 6 6840 25924227 10.1038/ncomms7840 PMC4423225

41. Belladonna ML Volpi C Bianchi R Vacca C Orabona C Pallotta MT Boon L Gizzi S Fioretti MC Grohmann U Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells J Immunol 2008 181 8 5194 5198 18832670 10.4049/jimmunol.181.8.5194

42. Pallotta MT Orabona C Volpi C Vacca C Belladonna ML Bianchi R Servillo G Brunacci C Calvitti M Bicciato S Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells Nat Immunol 2011 12 9 870 U91 21804557 10.1038/ni.2077

43. Kelly A Gunaltay S McEntee CP Shuttleworth EE Smedley C Houston SA Fenton TM Levison S Mann ER Travis MA Human monocytes and macrophages regulate immune tolerance via integrin alpha v beta 8-mediated TGF beta activation J Exp Med 2018 215 11 2725 36 30355614 10.1084/jem.20171491 PMC6219736

44. Arwert EN Harney AS Entenberg D Wang YR Sahai E Pollard JW Condeelis JS A unidirectional transition from migratory to perivascular macrophage is required for tumor cell intravasation Cell Rep 2018 23 5 1239 48 29719241 10.1016/j.celrep.2018.04.007 PMC5946803

45. Lee YS Park JS Kim JH Jung SM Lee JY Kim SJ Park SH Smad6-specific recruitment of Smurf E3 ligases mediates TGF-beta 1-induced degradation of MyD88 in TLR4 signalling Nat Commun 2011 2 460 21897371 10.1038/ncomms1469

46. Hong S Lim S Li AG Lee C Lee YS Lee EK Park SH Wang XJ Kim SJ Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2 Nat Immunol 2007 8 5 504 13 17384642 10.1038/ni1451

47. Pang Y Gara SK Achyut BR Li Z Yan HH Day CP Weiss JM Trinchieri G Morris JC Yang L TGF-beta signaling in myeloid cells is required for tumor metastasis Cancer Discov 2013 3 8 936 51 23661553 10.1158/2159-8290.CD-12-0527 PMC4678771

48. Li ZY Pang YL Gara SK Achyut BR Heger C Goldsmith PK Lonning S Yang L Gr-1+CD11b+cells are responsible for tumor promoting effect of TGF-ss in breast cancer progression Int J Cancer 2012 131 11 2584 95 22487809 10.1002/ijc.27572 PMC3433574

49. Jayaraman P Parikh F Newton JM Hanoteau A Rivas C Krupar R Rajapakshe K Pathak R Kanthaswamy K MacLaren C TGF-beta 1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy Oncoimmunology. 2018 7 10 1490853 10.1080/2162402X.2018.1490853 PMC6169570 30288358

50. Lee CR Lee W Cho SK Park SG Characterization of multiple cytokine combinations and TGF-beta on differentiation and functions of myeloid-derived suppressor cells Int J Mol Sci. 2018 19 3 730 10.3390/ijms19030869 PMC5877730 29543758

51. Li Z, Zhang LJ, Zhang HR, Tian GF, Tian J, Mao XL, Jia ZH, Meng ZY, Zhao LQ, Yin ZN, Wu ZZ. Tumor-derived transforming growth factor-β is critical for tumor progression and evasion from immune surveillance. Asian Pac J Cancer Prev. 2014;15(13):5181–6. 10.7314/apjcp.2014.15.13.5181. 10.7314/apjcp.2014.15.13.5181 25040972

52. Oh SA Li MO TGF-β: guardian of T cell function J Immunol 2013 191 8 3973 9 10.4049/jimmunol.1301843.PMID:24098055;PMCID:PMC3856438 24098055 PMC3856438

53. Tang N Cheng C Zhang X Qiao M Li N Mu W Wei XF Han W Wang H TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors JCI Insight 2020 5 4 e133977 10.1172/jci.insight.133977.PMID:31999649;PMCID:PMC7101140 PMC7101140 31999649

54. Kloss CC Lee J Zhang A Chen F Melenhorst JJ Lacey SF Maus MV Fraietta JA Zhao Y June CH Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication Mol Ther. 2018 26 7 1855 1866 10.1016/j.ymthe.2018.05.003 29807781 PMC6037129

55. Friedman E Gold LI Klimstra D Zeng ZS Winawer S Cohen A High-levels of transforming growth-factor-beta-1 correlate with disease progression in human colon cancer Cancer Epidem Biomar 1995 4 5 549 54 7549813

56. Lampropoulos P Zizi-Sermpetzoglou A Rizos S Kostakis A Nikiteas N Papavassiliou AG TGF-beta signalling in colon carcinogenesis Cancer Lett 2012 314 1 1 7 22018778 10.1016/j.canlet.2011.09.041

57. Bierie B Moses HL TGF beta: the molecular Jekyll and Hyde of cancer Nat Rev Cancer 2006 6 7 506 20 16794634 10.1038/nrc1926

58. Shen W Tao GQ Zhang Y Cai B Sun J Tian ZQ TGF-beta in pancreatic cancer initiation and progression: two sides of the same coin Cell Biosci 2017 7 739 10.1186/s13578-017-0168-0 PMC5545849 28794854

59. Abou-Shady M Baer HU Friess H Berberat P Zimmermann A Graber H Gold LI Korc M Buchler MW Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma Am J Surg 1999 177 3 209 15 10219856 10.1016/s0002-9610(99)00012-4

60. Lin TH Shao YY Chan SY Huang CY Hsu CH Cheng AL High serum transforming growth factor-beta 1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib Clin Cancer Res 2015 21 16 3678 84 25977342 10.1158/1078-0432.CCR-14-1954

61. Coskun HSI Ozcan M Ayaz S Dalva K Ustun C Arat M Serum transforming growth factor beta 1 levels in multiple myeloma patients Turk J Hematol 2006 23 1 47 52 27265228

62. Watanabe Y Iwamura A Shimada YJ Wakai K Tamakoshi A Iso H Grp JS Transforming growth factor-beta 1 as a predictor for the development of hepatocellular carcinoma: a nested case-controlled study Ebiomedicine 2016 12 68 71 27614396 10.1016/j.ebiom.2016.09.001 PMC5078582

63. Havel JJ Chowell D Chan TA The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Nat Rev Cancer 2019 19 3 133 50 30755690 10.1038/s41568-019-0116-x PMC6705396

64. Bai X Yi M Jiao Y Chu Q Wu K Blocking TGF-beta signaling to enhance the efficacy of immune checkpoint inhibitor Onco Targets Ther 2019 12 9527 38 31807028 10.2147/OTT.S224013 PMC6857659

65. Martin CJ Datta A Littlefield C Kalra A Chapron C Wawersik S Dagbay KB Brueckner CT Nikiforov A Danehy FT Selective inhibition of TGF beta 1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape Sci Transl Med 2020 12 536 10.1126/scitranslmed.aay8456 32213632

66. Huynh LK Hipolito CJ Ten Dijke P A perspective on the development of TGF-beta inhibitors for cancer treatment Biomolecules 2019 9 11 10.3390/biom9110743 PMC6921009 31744193

67. Ciardiello D Elez E Tabernero J Seoane J Clinical development of therapies targeting TGF beta: current knowledge and future perspectives Ann Oncol 2020 31 10 1336 49 32710930 10.1016/j.annonc.2020.07.009

68. Jin CH Krishnaiah M Sreenu D Subrahmanyam VB Rao KS Lee HJ Park SJ Park HJ Lee K Sheen YY Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2 -yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-beta type I receptor kinase as cancer immunotherapeutic/antifibrotic agent J Med Chem 2014 57 10 4213 38 24786585 10.1021/jm500115w

69. Son JY Park SY Kim SJ Lee SJ Park SA Kim MJ Kim SW Kim DK Nam JS Sheen YY EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis Mol Cancer Ther 2014 13 7 1704 16 24817629 10.1158/1535-7163.MCT-13-0903

70. Jung SY Hwang S Clarke JM Bauer TM Keedy VL Lee H Park N Kim SJ Lee JI Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study Invest New Drugs 2020 38 3 812 20 31300967 10.1007/s10637-019-00835-y

71. Jung SY Yug JS Clarke JM Bauer TM Keedy VL Hwang S Kim SJ Chung EK Lee JI Population pharmacokinetics of vactosertib, a new TGF-beta receptor type Iota inhibitor, in patients with advanced solid tumors Cancer Chemother Pharmacol 2020 85 1 173 83 31673825 10.1007/s00280-019-03979-z

72. Lee KW Park YS Ahn JB Rha SY Kim HK Lee PY Ryu MH Lee J Lee JK Hwang S Safety and anti-tumor activity of the transforming growth factor beta receptor I kinase inhibitor, vactosertib, in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer J Immunother Cancer 2020 8 Suppl. 3 A358

73. Han JY Pyo KH Kim JH Xin CF Lee JK Hwang S Kim SJ Cho BC Cho BC Safety and anti-tumor activity of the transforming growth factor beta receptor I kinase inhibitor, vactosertib, in combination with durvalumab in patients with advanced non-small cell lung cancer (NSCLC) J Immunother Cancer 2020 8 Suppl. 3 A388

74. Malek E Kim BG Valent J Driscoll J Caimi P Kim SJ de Lima M Letterio J Preclinical studies and a phase I trial of the tgf-beta receptor inhibitor, vactosertib (TEW-7197), in combination with pomalidomide in patients with multiple myeloma refractory to bortezomib or lenalidomide Blood 2018 132 Suppl. 1 1962

75. Malek E, Hwang S, de Lima M, Caimi P, Gallogly MM, Metheny L, Otegbeye F, Tomlinson BK, Boughan KM, Cooper B et al. Preclinical studies and phase i trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway. Blood. 2019;134(Supplement 1):3232.

76. Bataller A Montalban-Bravo G Soltysiak KA Garcia-Manero G The role of TGFbeta in hematopoiesis and myeloid disorders Leukemia 2019 33 5 1076 89 30816330 10.1038/s41375-019-0420-1 PMC11789621

77. Aluri S, Bachiashvili K, Budhathoki A, Bhagat TD, Choudhary GS, Gordon S, Ramachandra N, Pradhan K, Maqbool S, Shastri A, et al. Clinical ALK5 inhibitor, vactosertib, reverses TGFβ-1 stimulated Smad-2 driven ineffective hematopoiesis in MDS. Blood. 2019;134 (Suppl. 1):2990.

78. Tsukada T Fushida S Harada S Terai S Yagi Y Kinoshita J Oyama K Tajima H Ninomiya I Fujimura T Low-dose paclitaxel modulates tumour fibrosis in gastric cancer Int J Oncol 2013 42 4 1167 74 23443842 10.3892/ijo.2013.1801 PMC3622657

79. Fujiwara Y Nokihara H Yamada Y Yamamoto N Sunami K Utsumi H Asou H Takahash IO Ogasawara K Gueorguieva I Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 2015 76 6 1143 52 26526984 10.1007/s00280-015-2895-4

80. Rodon J Carducci M Sepulveda-Sanchez JM Azaro A Calvo E Seoane J Brana I Sicart E Gueorguieva I Cleverly A Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer Invest New Drugs 2015 33 2 357 70 25529192 10.1007/s10637-014-0192-4 PMC4387272

81. Herbertz S Sawyer JS Stauber AJ Gueorguieva I Driscoll KE Estrem ST Cleverly AL Desaiah D Guba SC Benhadji KA Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Drug Des Devel Ther 2015 9 4479 99 26309397 10.2147/DDDT.S86621 PMC4539082

82. Faivre SJ Santoro A Gane E Kelley RK Hourmand II Assenat E Gueorguieva I Cleverly A Desaiah D Lahn MMF A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-beta) receptor I kinase inhibitor in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP) J Clin Oncol 2016 34 15 4070

83. Gueorguieva I Cleverly AL Stauber A Sada Pillay N Rodon JA Miles CP Yingling JM Lahn MM Defining a therapeutic window for the novel TGF-beta inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model Br J Clin Pharmacol 2014 77 5 796 807 24868575 10.1111/bcp.12256 PMC4004400

84. Kovacs RJ Maldonado G Azaro A Fernandez MS Romero FL Sepulveda-Sanchez JM Corretti M Carducci M Dolan M Gueorguieva I Cardiac safety of TGF-beta receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study Cardiovasc Toxicol 2015 15 4 309 23 25488804 10.1007/s12012-014-9297-4 PMC4575352

85. Parente P, Parcesepe P, Covelli C, Olivieri N, Remo A, Pancione M, Latiano TP, Graziano P, Maiello E, Giordano G. Crosstalk between the tumor microenvironment and immune system in pancreatic ductal adenocarcinoma: potential targets for new therapeutic approaches. Gastroenterol Res Pract . 2018; 7530619. 10.1155/2018/7530619 PMC6312626 30662458

86. Melisi D Garcia-Carbonero R Macarulla T Pezet D Deplanque G Fuchs M Trojan J Oettle H Kozloff M Cleverly A A phase II, double-blind study of galunisertib plus gemcitabine (GG) vs gemcitabine plus placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC) J Clin Oncol 2016 34 15 1208 1214 30318515 10.1038/s41416-018-0246-z PMC6251034

87. Pei HX Parthasarathy S Joseph S McMillen W Xu XH Castaneda S Inigo I Britt K Anderson B Zhao GY LY3200882, a novel, highly selective TGF beta RI small molecule inhibitor Cancer Res 2017 77 13 955

88. Yap TBC, Massard C. First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-&beta; receptor type 1 (TGF-&beta;R1) inhibitor LY3200882 in patients with advanced cancer. In Proceedings from the 2018 SITC annual meeting. 2018; Abstract 030.

89. Gordon MS Ilaria R Jr de Alwis DP Mendelson DS McKane S Wagner MM Look KY LoRusso PM A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors Cancer Chemother Pharmacol 2013 71 1 21 7 23228983 10.1007/s00280-012-1917-8

90. Tojo M Hamashima Y Hanyu A Kajimoto T Saitoh M Miyazono K Node M Imamura T The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta Cancer Sci 2005 96 11 791 800 16271073 10.1111/j.1349-7006.2005.00103.x PMC11159601

91. Sim WJ Iyengar PV Lama D Lui SKL Ng HC Haviv-Shapira L Domany E Kappei D Tan TZ Saei A c-Met activation leads to the establishment of a TGF beta-receptor regulatory network in bladder cancer progression Nat Commun 2019 10 4349 31554791 10.1038/s41467-019-12241-2 PMC6761206

92. Melisi D Ishiyama S Sclabas GM Fleming JB Xia Q Tortora G Abbruzzese JL Chiao PJ LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol Cancer Ther 2008 7 4 829 40 18413796 10.1158/1535-7163.MCT-07-0337 PMC3088432

93. Connolly EC Saunier EF Quigley D Luu MT De Sapio A Hann B Yingling JM Akhurst RJ Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761 Cancer Res 2011 71 6 2339 49 21282335 10.1158/0008-5472.CAN-10-2941 PMC3059399

94. Bandyopadhyay A Agyin JK Wang L Tang YP Lei XF Story BM Cornell JE Pollock BH Mundy GR Sun LZ Inhibition of pulmonary and skeletal metastasis by a TGF-beta type I receptor kinase inhibitor Can Res 2006 66 13 6714 21 10.1158/0008-5472.CAN-05-3565 16818646

95. Ehata S Hanyu A Fujime M Katsuno Y Fukunaga E Goto K Ishikawa Y Nomura K Yokoo H Shimizu T Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line Cancer Sci 2007 98 1 127 33 17129361 10.1111/j.1349-7006.2006.00357.x PMC11159712

96. Shinto O Yashiro M Kawajiri H Shimizu K Shimizu T Miwa A Hirakawa K Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells Br J Cancer 2010 102 5 844 51 20145621 10.1038/sj.bjc.6605561 PMC2833252

97. Byfield SD, Roberts AB. Lateral signaling enhances TGF-beta response complexity. Trends Cell Biol. 2004; 14(3):107–11. 10.1016/j.tcb.2004.01.001 15055198

98. Sawyer TK Novel oncogenic protein kinase inhibitors for cancer therapy Curr Med Chem Anticancer Agents 2004 4 5 449 55 15379702 10.2174/1568011043352830

99. Matsuyama S Iwadate M Kondo M Saitoh M Hanyu A Shimizu K Aburatani H Mishima HK Imamura T Miyazono K SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells Cancer Res 2003 63 22 7791 8 14633705

100. Takeuchi K Abe M Hiasa M Oda A Amou H Kido S Harada T Tanaka O Miki H Nakamura S Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth PLoS ONE 2010 5 3 e9870 20360846 10.1371/journal.pone.0009870 PMC2845613

101. Uhl M Aulwurm S Wischhusen J Weiler M Ma JY Almirez R Mangadu R Liu YW Platten M Herrlinger U SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo Cancer Res 2004 64 21 7954 61 15520202 10.1158/0008-5472.CAN-04-1013

102. Mohammad KS Javelaud D Fournier PG Niewolna M McKenna CR Peng XH Duong V Dunn LK Mauviel A Guise TA TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases Cancer Res 2011 71 1 175 84 21084275 10.1158/0008-5472.CAN-10-2651 PMC3225124

103. Subramanian G Schwarz RE Higgins L McEnroe G Chakravarty S Dugar S Reiss M Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1 Cancer Res 2004 64 15 5200 11 15289325 10.1158/0008-5472.CAN-04-0018

104. Lee GT Hong JH Mueller TJ Watson JA Kwak C Sheen YY Kim DK Kim SJ Kim IY Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells J Urol 2008 180 6 2660 7 18951571 10.1016/j.juro.2008.08.008

105. Park CY Min KN Son JY Park SY Nam JS Kim DK Sheen YY An novel inhibitor of TGF-beta type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition Cancer Lett 2014 351 1 72 80 24887560 10.1016/j.canlet.2014.05.006

106. Morris JC Tan AR Olencki TE Shapiro GI Dezube BJ Reiss M Hsu FJ Berzofsky JA Lawrence DP Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma PLoS ONE 2014 9 3 e90353 24618589 10.1371/journal.pone.0090353 PMC3949712

107. Tolcher AW Berlin JD Cosaert J Kauh J Chan E Piha-Paul SA Amaya A Tang S Driscoll K Kimbung R A phase 1 study of anti-TGFbeta receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors Cancer Chemother Pharmacol 2017 79 4 673 80 28280971 10.1007/s00280-017-3245-5 PMC5893148

108. Fjellbirkeland L Cambier S Broaddus VC Hill A Brunetta P Dolganov G Jablons D Nishimura SL Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue Am J Pathol 2003 163 2 533 42 12875973 10.1016/s0002-9440(10)63681-4 PMC1868219

109. Eberlein C Kendrew J McDaid K Alfred A Kang JS Jacobs VN Ross SJ Rooney C Smith NR Rinkenberger J A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo Oncogene 2013 32 37 4406 16 23108397 10.1038/onc.2012.460

110. Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, et al. Therapeutic targeting of integrin alphavbeta6 in breast cancer. J Natl Cancer Inst. 2014;106(8). 10.1093/jnci/dju169 PMC4151855 24974129

111. Nam JS Terabe M Mamura M Kang MJ Chae H Stuelten C Kohn E Tang B Sabzevari H Anver MR An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments Cancer Res 2008 68 10 3835 43 18483268 10.1158/0008-5472.CAN-08-0215 PMC2587151

112. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993; 92(6):2569–76. 10.1172/JCI116871 PMC288452 7504687

113. Ganapathy V Ge R Grazioli A Xie W Banach-Petrosky W Kang Y Lonning S McPherson J Yingling JM Biswas S Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis Mol Cancer. 2010 9 122 1 16 20504320 10.1186/1476-4598-9-122 PMC2890606

114. O'Connor-McCourt MD Tremblay G Lenferink A Sulea T Zwaagstra J Koropatnick J AVID200, a highly potent TGF-beta trap, exhibits optimal isoform selectivity for enhancing anti-tumor T-cell activity, without promoting metastasis or cardiotoxicity Cancer Res 2018 78 13 1759

115. Strauss J Heery CR Schlom J Madan RA Cao L Kang ZG Lamping E Marte JL Donahue RN Grenga I Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF beta Adv Solid Tumors Clin Cancer Res 2018 24 6 1287 95 10.1158/1078-0432.CCR-17-2653 PMC7985967 29298798

116. Paz-Ares L Kim TM Vicente D Felip E Lee DH Lee KH Lin CC Flor MJ Di Nicola M Alvarez RM Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial J Thorac Oncol 2020 15 7 1210 22 32173464 10.1016/j.jtho.2020.03.003 PMC8210474

117. Birrer MJ Mileshkin LR Fujiwara K Ray-Coquard I Alexandre J Okamoto A Mirza MR Gulley JL Jehl G Ramage S Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in platinum-experienced advanced cervical cancer Ann Oncol. 2020 31 S644 S5

118. Fenaux P Platzbecker U Mufti GJ Garcia-Manero G Buckstein R Santini V Diez-Campelo M Finelli C Cazzola M Ilhan O Luspatercept in patients with lower-risk myelodysplastic syndromes New Engl J Med 2020 382 2 140 51 31914241 10.1056/NEJMoa1908892

119. Bandyopadhyay A Lopez-Casillas F Malik SN Montiel JL Mendoza V Yang J Sun LZ Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft Cancer Res 2002 62 16 4690 5 12183427

120. Muraoka RS Dumont N Ritter CA Dugger TC Brantley DM Chen J Easterly E Roebuck LR Ryan S Gotwals PJ Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases J Clin Invest 2002 109 12 1551 9 12070302 10.1172/JCI15234 PMC151012

121. Gleave ME Monia BP Antisense therapy for cancer Nat Rev Cancer 2005 5 6 468 79 15905854 10.1038/nrc1631

122. Dias N Stein CA Antisense oligonucleotides: basic concepts and mechanisms Mol Cancer Ther 2002 1 5 347 55 12489851

123. Tibbitt MW Dahlman JE Langer R Emerging frontiers in drug delivery J Am Chem Soc 2016 138 3 704 17 26741786 10.1021/jacs.5b09974

124. Schlingensiepen KH Schlingensiepen R Steinbrecher A Hau P Bogdahn U Fischer-Blass B Jachimczak P Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009 Cytokine Growth Factor Rev 2006 17 1–2 129 39 16377233 10.1016/j.cytogfr.2005.09.002

125. Jaschinski F Rothhammer T Jachimczak P Seitz C Schneider A Schlingensiepen KH The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2 Curr Pharm Biotechnol 2011 12 12 2203 13 21619536 10.2174/138920111798808266

126. Hau P Jachimczak P Bogdahn U Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides Expert Rev Anticancer Ther 2009 9 11 1663 74 19895249 10.1586/era.09.138

127. Oh J Barve M Matthews CM Koon EC Heffernan TP Fine B Grosen E Bergman MK Fleming EL DeMars LR Phase II study of Vigil DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer Gynecol Oncol 2016 143 3 504 10 27678295 10.1016/j.ygyno.2016.09.018

128. Tong AW Small RNAs and non-small cell lung cancer Curr Mol Med 2006 6 3 339 49 16712479 10.2174/156652406776894554

129. Giaccone G Bazhenova LA Nemunaitis J Tan M Juhasz E Ramlau R van den Heuvel MM Lal R Kloecker GH Eaton KD A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer Eur J Cancer 2015 51 16 2321 9 26283035 10.1016/j.ejca.2015.07.035

130. Jakowlew SB Mathias A Chung P Moody TW Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines Cell Growth Differ 1995 6 4 465 76 7794814

131. Constam DB Philipp J Malipiero UV ten Dijke P Schachner M Fontana A Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia J Immunol 1992 148 5 1404 10 1538124

132. Nemunaitis J Dillman RO Schwarzenberger PO Senzer N Cunningham C Cutler J Tong A Kumar P Pappen B Hamilton C Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 2006 24 29 4721 30 16966690 10.1200/JCO.2005.05.5335

133. Rook AH Kehrl JH Wakefield LM Roberts AB Sporn MB Burlington DB Lane HC Fauci AS Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness J Immunol 1986 136 10 3916 20 2871107

134. Tsunawaki S Sporn M Ding A Nathan C Deactivation of macrophages by transforming growth factor-beta Nature 1988 334 6179 260 2 3041283 10.1038/334260a0